Moderna will start human trials of AIDS vaccine with mRNA technologynext Wednesday, using the technology similar to COVID-19 vaccine
Moderna will start human trials of AIDS vaccine with mRNA technology as early as Wednesday, using the same messenger RNA platform as its COVID-19 vaccine.
An entry published on Wednesday in the National Institutes of Health Clinical Trials Registry shows that the trial is expected to begin on August 19 and will be completed in the spring of 2023.
Moderna has two candidate HIV vaccines, mRNA-1644 and mRNA-1644v2-Core. These two vaccines have passed preliminary safety tests before they were first used in humans. The randomized trial will include 56 HIV-negative participants between the ages of 18 and 56.
HIV is one of several viruses that Moderna uses the messenger RNA platform to develop vaccines. Madner vaccine and Pfizer/BioNTech’s 2019 coronavirus disease vaccine are the first mRNA vaccines approved for human use in the United States, although this technology has been developed for decades and has gradually matured with the emergence of a pandemic.
Efforts to develop an HIV vaccine have been ongoing for decades, but with little success. Although a variety of candidate vaccines have entered the experimental stage, not all vaccines are safe, and almost no vaccine has shown even general effectiveness.
A vaccine tested in Thailand in 2000, which may be the most effective candidate vaccine, was found to reduce infections by about 30%, although some scientists believe that the test results are controversial.
In the same decade, scientists were forced to cancel the trial of another vaccine candidate because they discovered that this vaccine may actually increase the risk of HIV infection, rather than prevent infection.
Unlike Moderna vaccine candidates, none of the previous HIV vaccine candidates were developed using mRNA. Since the messenger ribonucleic acid platform provides a new method and has been proven to be safe and effective, scientists hope that it will lead to the breakthrough of the HIV virus in the 2019 coronavirus disease.
In addition, due to the nature of HIV, messenger RNA technology may have some obvious advantages over traditional methods. For decades, HIV has rapidly mutated into many different variants.
Dr. Rajesh Gandhi, President of the Infectious Diseases and AIDS Medical Association, told Verywell Health, “This mRNA platform makes it easy to develop vaccines against mutations because it only needs to update the coding sequence that encodes the mutant mRNA.”.
He added: “Based on the success of mRNA technology in preventing the COVID-19 virus, I hope that mRNA technology will completely change our ability to develop vaccines for other pathogens, such as HIV and influenza.”.
Several other companies are also developing AIDS vaccines. Some candidate vaccines are currently or are about to enter clinical trials. Other vaccines have been developed using a variety of methods, including technology used in a partially successful Thai trial.
The COVID-19 epidemic has accelerated the maturity of mRNA vaccine technology. At the same time, this technology is also a technology that can achieve mass production as soon as possible. We look forward to better test results.
(source: internet, reference only)